sur CROSSJECT (EPA:ALCJ)
Crossject announces a fundraising of 7 million euros
Crossject, a specialty pharmaceutical company, announces a €7 million private placement. The transaction includes a capital increase and the issuance of warrants reserved for qualified investors. Maxim Group LLC and Invest Securities are acting as lead agents. The funds will support the development of ZEPIZURE®, a needle-free auto-injector, prior to an application for FDA approval.
More than half of the funds will be allocated to the development of ZEPIZURE®, with the remainder supporting R&D and other projects. The funding will enable Crossject to cover its needs until mid-2025. Shareholder Gemmes Venture, together with Heights Capital Management, will make a significant contribution to this transaction.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de CROSSJECT